EpiDermLab
Laboratorium badawcze

DERMATOLOGICAL TEST REPORT OF A HOUSEHOLD PRODUCT
STANDARD SEMI-OPEN PATCH TEST

REPORT NUMBER	26/515/DZ/V1
PRODUCT NAME / CODE	PUELLA SUNNY BLOOM
PANEL	NORMAL SKIN
NUMBER OF VOLUNTEERS	20
TEST DATE	30.06.2026 - 03.07.2026
SUPERVISION	DERMATOLOGIST
CUSTOMER	PUELLAVONE S.R.O. ROVNÍKOVÁ 1457/7 040 12 KOŠICE - MESTSKÁ ČASŤ NAD JAZEROM, SLOVAKIA
TESTING LABORATORY	EPIDERMLAB LABORATORIUM BADAWCZE S.C. UL. ŁOWIENICKA 14/3 30-613 KRAKÓW, POLAND
REPORT DATE	06.07.2026

CONTENTS

1. SUBJECT OF THE STUDY

The subject of the study was the household product PUELLA SUNNY BLOOM intended for use as a fabric softener.

Form	liquid
Color	milky
Scent	fragrance composition
Packaging	replacement packaging
Declared ingredients	Esterification products of fatty acids, C16–18 (even numbered) and C18 (unsaturated) with Triethanolamine, Timethyl Sulphate-quaternized, Methylchloroisothiazolinone (and) Methylisothiazolinone.
Storage	at 20–24 ° C and protected from light, for 1 month after completion of the test. After this period, the product should be disposed of.

2. PURPOSE OF THE STUDY

To assess skin tolerance to the household product, an evaluation of its irritant potential was performed on healthy adult volunteers using a single-application standard semi-open patch test. The study was designed to assess the skin compatibility of the tested product under the experimental conditions of the study.

3. VOLUNTEERS

3.1. INCLUSION CRITERIA

- Healthy individuals aged 18 to 70 years,
- Individuals who have given informed, written consent,
- Individuals with no history of intolerance or allergic reactions to household products or their ingredients.

3.2. EXCLUSION CRITERIA

- Pregnant and breastfeeding women,
- Individuals currently taking or who have stopped taking:
- Antihistamines, antibiotics, systemic anti-inflammatory drugs in the last week,
- Cough medicines, corticosteroids used in the last 4 weeks,
- Retinoids, immunosuppressive drugs, anticancer drugs in the last 6 months,
- Individuals who have started, discontinued, or changed hormonal treatment (including contraceptive pills) in the last 5 weeks,
- Individuals with highly irritated skin,
- Individuals showing significant back hair or tattoos on the application site,
- Individuals suffering from serious illnesses,
- Individuals abusing alcohol or tobacco,
- Volunteers involved in a similar study at another laboratory.

3.3. EARLY TERMINATION OF THE STUDY

Volunteers had the right to withdraw from the study at any time without providing a reason. The study supervisors could exclude a participant due to non-compliance or adverse events.

3.4. CHARACTERISTICS OF VOLUNTEERS

Number	20
Gender	women: 20, men: 0
Average age (years)	50 (range: 22 to 70)
Skin sensitivity (number of volunteers)	sensitive: 0, non-sensitive: 20

4. METHODS

4.1. TOOLS, DOSAGE, DURATION

Application site	back or arm
Test type	fabric rinsed with an area of 1 cm^2
Application time	48 hours
Control test	Untreated fabric specimen

4.2. READINGS AND EVALUATION SCALE

Skin readings were performed 15 minutes after removal of the test material following 48 hours of application (first reading). An additional follow-up reading was performed 72 hours after the beginning of the test to confirm the absence of delayed skin reactions.

If no local skin reaction ≥1 was observed, the study was concluded. If a visible reaction occurred, the volunteer was required to return to the laboratory for further readings until the skin reaction subsided.

Scale	Meaning	Description
0 / -	negative	none
0.5 / ?+	doubtful	slight erythema, erythematous spot not palpable. This type of reaction is usually not considered indicative of sensitization.
1 / +	weak	palpable erythematous focus suggesting mild swelling/infiltration, with or without papules, no vesicles.
2 / ++	strong	intensified swelling, infiltration, papules, vesicles present.
3 / +++	extremely strong	"blisters" formed by confluence of vesicles or erosion.



4.3. INTERPRETATION OF RESULTS

The average irritation index (x_{avg}) was calculated as the sum of all individual scores divided by the number of observations.

$$\mathbf{x_{avg}} = \frac{\textbf{sum of the classification scores}}{\textbf{number of volunteers}}$$

Average Irritation Index (x_{avg})	Product classification
$x_{avg} < 0.5$	Non-irritating
$0.5 \leq x_{avg} < 2.0$	Mildly irritating
$2.0 \leq x_{avg} < 5.0$	Moderately irritating
$5.0 \leq x_{avg}$	Strongly irritating

5. RESULTS

Volunteer	Age	Gender F- female, M - male	Application site B – back, A - arm	Reading after 48h		Reading after 72h	
				Control	Tested product	Control	Tested product
1.	52	F	A	0	0	0	0
2.	70	F	A	0	0	0	0
3.	49	F	A	0	0	0	0
4.	56	F	A	0	0	0	0
5.	70	F	A	0	0	0	0
6.	70	F	A	0	0	0	0
7.	65	F	A	0	0	0	0
8.	70	F	B	0	0	0	0
9.	22	F	A	0	0	0	0
10.	54	F	A	0	0	0	0
11.	24	F	A	0	0	0	0
12.	48	F	A	0	0	0	0
13.	48	F	A	0	0	0	0
14.	23	F	A	0	0	0	0
15.	54	F	A	0	0	0	0
16.	51	F	A	0	0	0	0
17.	53	F	A	0	0	0	0
18.	50	F	A	0	0	0	0
19.	26	F	B	0	0	0	0
20.	52	F	B	0	0	0	0

The following table presents the calculated average irritation index (xavg) together with the corresponding irritation classification of the tested household product.

Average Irritation Index (x_{avg})	Classification
0.00	NON-IRRITATING

6. CONCLUSIONS

Based on the conducted standard semi-open patch test, it was concluded that the tested household product:

PUELLA SUNNY BLOOM

- demonstrated excellent skin tolerance under the conditions of the study and did not induce clinically significant irritation reactions in the study group;
- the calculated average irritation index (xavg = 0.00) classified the product as non-irritating under the experimental conditions of the study;
- the obtained results support very good skin compatibility of the tested household product under the conditions of the study and support its intended use.

7. COMMENTS

- The issued report does not apply to individuals with a documented allergy to any ingredient of the product.
- The Customer is responsible for ensuring that the tested sample is consistent with the declared qualitative composition and meets microbiological purity requirements.
- The results presented in this report apply exclusively to the tested sample.
- The conclusions presented in this report apply exclusively to the tested product under the conditions of this study.
- This test report has been prepared in a single original copy:

- Original: Customer,
- Copy No. 1: Archive.

8. AUTHORIZATION

Report prepared by	Study Supervisor	Report authorized by
Violetta Majda	Dr. Agnieszka Snarska-Drygalska	Anna Kwiatkowska
Research Specialist	Specialist in Dermatology and Venereology	Laboratory Director
(qualified electronic signature)	2294120	*(qualified electronic signature)*
Signature Not Verified Dokument podpisany przez Violetta Majda Data: 2026.07.06 15:03:22 CEST		Signature Not Verified Dokument podpisany przez Anna Kwiatkowska Data: 2026.07.06 15:29:57 CEST

END OF REPORT